Siramesine H Lundbeck

Curr Opin Investig Drugs. 2001 Feb;2(2):266-70.

Abstract

Siramesine is a sigma2 opioid agonist under development by H Lundbeck as a potential treatment for anxiety 11678721. In March 1998, the compound was licensed to Forest Laboratories under a strategic alliance [282593]. In August 2000, siramesine entered phase II trials [378814]. Phase III trials are expected to take place in 2002 [387270]. A series of compounds have been synthesized by Lundbeck, the most potent of which may serve as a backup compound [179036].

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Anxiety Agents / pharmacokinetics
  • Anti-Anxiety Agents / therapeutic use*
  • Anti-Anxiety Agents / toxicity
  • Anxiety / drug therapy*
  • Anxiety / psychology
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Female
  • Humans
  • Indoles / pharmacology
  • Indoles / therapeutic use*
  • Indoles / toxicity
  • Male
  • Receptors, sigma / agonists*
  • Spiro Compounds / pharmacology
  • Spiro Compounds / therapeutic use*
  • Spiro Compounds / toxicity
  • Structure-Activity Relationship

Substances

  • Anti-Anxiety Agents
  • Indoles
  • Lu 28-179
  • Receptors, sigma
  • Spiro Compounds